Europe
Aggressive, highly mutated cancers evolve escape routes in response to immune attacks in an ‘evolutionary arms race’ between cancer and the immune system, a new study reports.
DLA Piper is pleased to announce that the firm represented Osceola Capital, a middle-market private equity firm focused on services businesses, in its acquisition of Healthcents, Inc., a leading provider of medical reimbursement and related services.
Recipharm AB, through its directly wholly-owned subsidiary Recipharm Holdings Limited, published an offer document setting out the full terms and conditions of its recommended cash offer to acquire the entire issued and to be issued share capital of Consort Medical plc .
Raremark, the leading patient-data platform in rare disease, is pleased to announce additions to its executive team to speed the company’s pursuit of more treatments for rare medical conditions.
Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
ProBioGen AG and Lava Therapeutics B.V. announced the closing of a cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate..
Here’s a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what they’ve been up to recently.
Pharma companies add new members to executive ranks and boards of directors.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
“We are excited to sign this acquisition agreement with Bayer, allowing us to have quick access to high-quality drug product manufacturing capacities and capabilities,” said Chris Chen, chief executive officer of WuXi Biologics.
PRESS RELEASES